retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Eli Lilly's shows promising weight loss results in trial Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide
Description
Conclusions GLP-1RA demonstrated phenotype-specific benefits, improving structural remodeling in HFpEF but showing limited effects in HFrEF
with a GLP-1
As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)
In this randomized clinical trial ...
